Company profile: Immedica
1.1 - Company Overview
Company description
- Provider of niche/specialty care pharmaceutical products with commercial coverage across Europe and the Middle East. Portfolio includes Akynzeo for prevention of chemotherapy-induced nausea and vomiting; Ammonaps for urea cycle disorders; Arlevert for vertigo and tinnitus; Loargys for Arginase 1 Deficiency; Neofordex high-dose dexamethasone; and Nor-NOHA Blood Collection Tubes for blood collection and diagnostic purposes.
Products and services
- Loargys: Rare-disease-specific treatment engineered for patients with Arginase 1 Deficiency, precisely targeting this genetic disorder’s clinical management within niche specialty care
- Ammonaps: Ammonia-removal medication for urea cycle disorders, helping remove ammonia from the blood to manage these disorders in niche specialty care
- Neofordex: High-dose dexamethasone treatment for multiple myeloma and other conditions, enabling intensified dosing within specialty care protocols
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Immedica
Medivation
HQ: United States
Website
- Description: Provider of biopharmaceutical R&D focused on rapid development of small‑molecule drugs to treat serious diseases with limited treatment options, including the development of MDV3100 for multiple stages of advanced prostate cancer in collaboration with Astellas Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medivation company profile →
Lymphatica Medtech
HQ: Switzerland
Website
- Description: Provider of medical device development, creating a minimally invasive solution for chronic lymphedema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lymphatica Medtech company profile →
PDC Line Pharma
HQ: France
Website
- Description: Provider of clinical-stage active cancer immunotherapies based on an allogeneic plasmacytoid dendritic cell line (PDC*line) loaded with cancer antigens, including PDC*lung01, a therapeutic vaccine for non-small cell lung cancer used with anti-PD-1 to induce specific immune responses, and GeniusVac-Mel4, a vaccine designed to prime and expand antitumor T-cells in melanoma patients.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PDC Line Pharma company profile →
Armune Bioscience
HQ: United States
Website
- Description: Provider of molecular diagnostic and prognostic tests for prostate, lung and breast cancers, enabling physicians and patients to make more personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Armune Bioscience company profile →
Remix Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule medicines and an RNA-processing drug discovery platform. Offers REMaster to design modulators, supported by machine-learning data science on a transcriptome database, biology and biomolecular sciences with multiplexed HT screening, and medicinal/computational chemistry. Pipeline targets oncology and neurodegeneration, including REM-422, an mRNA degrader targeting MYB for ACC and AML, in Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Remix Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Immedica
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Immedica
2.2 - Growth funds investing in similar companies to Immedica
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Immedica
4.2 - Public trading comparable groups for Immedica
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →